收藏切换
Xueshuantong improves cerebral microcirculation disorder: action mechanism based on network pharmacology and experimental validation
收藏切换
PDF
Gao-rui WANG1, Zi-yu CHEN1, Hui WU1, Ying-ping LIU1, Ming CHEN2, Shu-sheng LAI2, Xiao-jun WU1, *, Zheng-tao WANG1
Acta Pharmaceutica Sinica | 2022, 57(7) : 2077 - 2086
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(7): 2077-2086
Original Articles
Xueshuantong improves cerebral microcirculation disorder: action mechanism based on network pharmacology and experimental validation
Full
Gao-rui WANG1, Zi-yu CHEN1, Hui WU1, Ying-ping LIU1, Ming CHEN2, Shu-sheng LAI2, Xiao-jun WU1, *, Zheng-tao WANG1
Affiliations
  • 1. Institute of Chinese Materia Medica of Shanghai University of Traditional Chinese Medicine and Shanghai Key Laboratory of Compound Chinese Medicines, Shanghai 201203, China
  • 2. Guangxi Key Laboratory of Comprehensive Utilization Technology of Pseudo-ginseng, Wuzhou 543002, China
Published: 2022-07-12 doi: 10.16438/j.0513-4870.2021-1858
Outline
收藏切换

This study is to explore the mechanism of Xueshuantong improving cerebral microcirculation disorder through the combination of network pharmacology and experimental validation in vivo. Structural formulas of main Panax notoginseng saponins, including notoginsenoside R1, and ginsenoside Rg1, Re, Rb1 and Rd were obtained from Pubchem website and their potential targets were predicted by Swiss Target Prediction database. Potential molecular targets of brain microcirculation disorder were acquired from OMIM and GeneCards database. The overlapped molecular targets between the drug and disease were analyzed. Protein interaction analysis and topology maps were constructed through the STRING online analysis platform and Cytoscape software. Core action targets were selected. GO function and KEGG pathway were analyzed by DAVID database. Immunohistochemical method was used to examine the expression of platelet endothelial cell adhesion molecule-1 (CD31) in the ischemic cortex of middle cerebral artery occlusion and reperfusion (MCAO/R) rats. The levels of mRNA and protein expressions of core action targets in MCAO/R model rats′ brain microvessels were verified by RT-qPCR and Western blot. Based on network pharmacology, 242 targets of Xueshuantong, 425 targets of brain microcirculation disorder, and 35 overlapped targets were obtained. The potential key targets of Xueshuantong, protein kinase B (AKT1), vascular endothelial growth factor A (VEGFA), caspase 3 (CASP3), matrix metallopeptidase 9 (MMP-9), phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), signal transducer and activator of transcription 3 (STAT3) involved in the alleviation of cerebral microcirculation disorder were obtained by setting degree and betweenness centrality as screening parameters. Xueshuantong at the dose of 48 mg·kg-1 was shown to significantly improve the injury of neurological behaviors, as well as the density and morphology of microvessels of MCAO/R model rats. Xueshuantong could down-regulate the mRNA levels of AKT1, MMP-9, and STAT3, increase the protein expression levels of CD31, phosphorylated AKT and phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K), and the ratio of B-cell lymphoma 2/Bcl-2-associated X (Bcl-2/Bax), but decrease the protein expression levels of MMP-9, cleaved caspase-3 and phosphorylated STAT3. In summary, Xueshuantong could improve ischemic cerebral microcirculation disorder and thereby reduce nerve damage in ischemia-reperfusion rats by regulating signaling pathways related with PI3K, AKT, MMP-9, STAT3 and caspase-3 in microvessels. The study strictly adhered to all ethical protocols that experimental animals should follow in the course of medical research.

network pharmacology  /  Xueshuantong  /  notoginsenoside  /  cerebral ischemia  /  brain microcirculation disorder
Gao-rui WANG, Zi-yu CHEN, Hui WU, Ying-ping LIU, Ming CHEN, Shu-sheng LAI, Xiao-jun WU, Zheng-tao WANG. Xueshuantong improves cerebral microcirculation disorder: action mechanism based on network pharmacology and experimental validation[J]. Acta Pharmaceutica Sinica, 2022 , 57 (7) : 2077 -2086 . DOI: 10.16438/j.0513-4870.2021-1858
Year 2022 volume 57 Issue 7
PDF
162
66
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2021-1858
  • Receive Date:2021-12-28
  • Online Date:2025-12-23
  • Published:2022-07-12
Article Data
Affiliations
History
  • Received:2021-12-28
  • Revised:2022-03-08
Funding
Affiliations
    1. Institute of Chinese Materia Medica of Shanghai University of Traditional Chinese Medicine and Shanghai Key Laboratory of Compound Chinese Medicines, Shanghai 201203, China
    2. Guangxi Key Laboratory of Comprehensive Utilization Technology of Pseudo-ginseng, Wuzhou 543002, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2021-1858
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT